VPC
REGN icon

Vestal Point Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Vestal Point Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.9M Buy
+40,000
New +$30.6M 0.86% 39
2025
Q4 		– Sell
-25,000
Closed -$14.1M – 102
2025
Q3 		$14.1M Buy
+25,000
New +$14.1M 0.63% 48
2025
Q1 		– Sell
-20,000
Closed -$14.2M – 78
2024
Q4 		$14.2M Buy
+20,000
New +$16.8M 0.84% 36
2024
Q1 		– Sell
-10,000
Closed -$8.78M – 71
2023
Q4 		$8.78M Buy
+10,000
New +$8.23M 0.93% 27

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vestal Point Capital's REGN Position: Q1 2026 in Review

Vestal Point Capital opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 40,000 shares worth $30.9M. The stake represents 0.86% of the portfolio and ranks #39 among its holdings. This is a return to the name: Vestal Point Capital previously reported a position in REGN as recently as Q3 2025.

Vestal Point Capital first reported a position in REGN in Q4 2023 and has held it in 4 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Vestal Point Capital held 40,000 shares of Regeneron Pharmaceuticals worth $30.9M as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Vestal Point Capital position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.86% of Vestal Point Capital's portfolio in Q1 2026, its #39 holding.
  • Vestal Point Capital first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.